- Case report
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Primary PEComa of the bladder treated with primary excision and adjuvant interferon-alpha immunotherapy: a case report
© Parfitt et al; licensee BioMed Central Ltd. 2006
Received: 18 April 2006
Accepted: 22 August 2006
Published: 22 August 2006
Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms of uncertain malignant potential, which have in common the co-expression of muscle and melanocytic immunohistochemical markers.
A 48-year-old man presented with dysuria, passage of urinary sediment and lower abdominal discomfort. A three centimeter mass was identified by cystoscopy in the posterior midline of the bladder. Computerized tomography suggested an enterovesical fistula. The patient underwent laparotomy, partial cystectomy and partial small bowel resection. Pathological examination revealed PEComa of the bladder. The patient underwent adjuvant interferon-α immunotherapy. Subsequent follow-up procedures, including cystoscopy and imaging, have not revealed evidence of recurrence. The patient is clinically free of disease 48 months after surgery.
This case represents the second documented PEComa of bladder and demonstrates that adjuvant therapies, including anti-angiogenic and immunotherapy, may be considered for patients with locally advanced or metastatic genitourinary PEComa.
Primary perivascular epithelioid cell tumors (PEComas) are a rare and unusual group of mesenchymal neoplasms with unpredictable malignant potential. The term "PEComa" was originally coined by Zamboni et al and is the current nomenclature for tumors composed of PECs other than angiomyolipoma (AML), clear cell sugar tumor of lung (CCST) and lymphangioleiomyomatosis (LAM), which are related lesions with distinct clinical features . Consequent to the World Health Organization's (WHO) endorsement of PEComa as a bonafide entity, an increasing number of reports have documented PEComas arising in varied anatomic locations, including bladder, kidney and prostate [2–8]. Despite increasing awareness of this entity, accurately predicting the biological behavior of PEComas remains difficult and contemporary reports are limited by short clinical follow-up. Herein, we report the diagnosis, management and four-year follow-up of the second documented case of primary PEComa of the urinary bladder .
A 48-year-old man presented with dysuria, passage of urinary sediment and lower abdominal discomfort. A three-centimeter (cm) smooth, lobular mass with mild bullous edema was identified by cystoscopy in the posterior midline of the bladder. Laboratory and staging investigations were negative and computerized tomography (CT) suggested an enterovesical fistula. The patient underwent laparotomy, partial cystectomy and partial small bowel resection. Pathological examination revealed PEComa of the bladder. A search for primary melanoma was negative and there were no stigmata of tuberous sclerosis. The patient underwent adjuvant interferon (IFN)-α immunotherapy for primary PEComa of the bladder. Subsequent follow-up evaluations were performed 3 monthly for the first 12 months, then 6 monthly thereafter. Routine follow-up procedures included clinical examination, cystoscopy, chest roentgenography, CT of abdomen and pelvis and routine blood work. On one occasion, positron emission tomography was performed in order to detect neoplastic metabolic activity. None of these follow-up procedures revealed evidence of recurrence. The patient is clinically free of disease 48 months after surgery.
The WHO has offered formal recognition to a group of neoplasms with perivascular epithelioid cell differentiation . These tumors have in common the presence of epithelioid to spindle cells with eosinophilic to clear cytoplasm that, with few exceptions, demonstrate positive immunostaining for markers of both myoid (smooth muscle actin, desmin) and melanocytic (HMB45, Melan-A, tyrosinase) differentiation. Pathologically, the main differential diagnoses include paraganglioma, melanoma, clear cell sarcoma of soft parts (CCSSP), metastatic carcinoma (especially from kidney or adrenal gland) and epithelioid sarcoma.
While distinct clinicopathological entities included within the PEComa group include AML, LAM and CCST, other PEC-derived tumors have been documented at an increasing number of anatomical sites, including pancreas, small and large intestine, ligamentum teres/falciform ligament, common bile duct, bladder, prostate, breast, uterus, cervix, vulva, ovary, broad ligament, heart, base of skull, and soft tissue [3–8]. The term "PEComa" has become the popular umbrella term for this latter list of lesions. Only one case of primary bladder PEComa has been described previous to ours. Pan et al reported a case of PEComa occurring in the deep detrusor muscle of the bladder in a 33-year-old woman, which was an incidental discovery during work-up for dysmenorrhea . While there were no worrisome clinicopathological features of the tumor and the patient remained tumor free during the entire six-year follow-up period, there was no description of post-operative treatment.
PEComas demonstrate uncertain tumor biology and unpredictable clinical behavior. While the majority of reported "PEComas" have behaved in a benign fashion, an important minority have demonstrated malignant behavior with locally destructive recurrences, distant metastases and patient death, underscoring the need for accurate identification and effective treatment strategies [4, 5, 7]. When Folpe et al combined results of 24 of their own cases of PEComa of soft tissue and gynecological origin with data from 45 previously reported cases of PEComa, they found that recurrence and metastasis were associated with tumor size >5 cm, infiltrative growth pattern, high nuclear grade, necrosis and a mitotic index of >1 per 50 high power fields [9, 10]. However, other authors feel that accurate criteria which reliably predict the behavior of PEComas remain lacking . In the present case, the surgical margins were not evaluable, due to the fragmented nature of the specimen, and lymph nodes were not sampled, since the intraoperative impression was that of a benign enterovesical fistula, rather than a potentially malignant neoplasm.
Optimal treatment for PEComas is not known at this time. Primary excision is usually curative, as most tumors are benign. However, locally advanced or metastatic disease portends a poor prognosis and strategies incorporating chemotherapy, radiation and immunotherapy have been reported. In this patient, a one-year course of adjuvant IFN-α 2b at 10 million units given subcutaneously three times per week was initiated based on the vascular nature of this tumor and IFN-α's additional anti-angiogenic effect . While IFN-α 2b therapy for the management of PEComa remains experimental, other authors have described the efficacy of IFN-α 2a in causing regression of life-threating hemangiomas in infants [12, 13]. While fever, neutropenia and skin necrosis have been reported as uncommon, short-term side effects of IFN-α 2a, no such effects were seen in the present case . As there was no evidence of residual tumor in the present case, a limitation of our report would be that the effect of IFN-α on PEComa morphology could not be documented. Thus, further studies are needed to clarify the clinical and pathological effects of IFN-α therapy in patients with PEComa and the risks of IFN therapy should be weighed against the potential benefits in any patient lacking detectable residual tumor. Partial, complete and absent responses have also been noted for dacarbazine, vincristine and imatinib mesylate, a tyrosine-kinase inhibitor . Adjuvant radiation for CCSSP has also been reported following wide surgical excision, with primary site irradiation appearing to confer a survival benefit for disease located in soft tissue of the extremities .
In summary, we report the first case of PEComa of the bladder treated with adjuvant IFN-α immunotherapy, with long-term follow-up. Given the uncertainty of PEComa tumor biology, adjuvant therapies, including anti-angiogenic and immunotherapy, may be considered for patients with locally advanced or metastatic genitourinary PEComa.
Consent was obtained from the patient for publication.
- Zamboni G, Pea M, Martignoni G, Zancanaro C, Faccioli G, Gilioli E, Pederzoli P, Bonetti F: Clear cell "sugar" tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells. Am J Surg Pathol. 1996, 20: 722-730. 10.1097/00000478-199606000-00010.View ArticlePubMedGoogle Scholar
- Folpe AL: Neoplasms with perivascular epithelioid cell differentiation (PEComas). World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2002, Lyon: IARC Press, 221-222.Google Scholar
- Evert M, Wardelmann E, Nestler G, Schulz HU, Roessner A, Rocken C: Abdominopelvic perivascular epithelioid cell sarcoma (malignant PEComa) mimicking gastrointestinal stromal tumor of the rectum. Histopathology. 2005, 46: 115-117. 10.1111/j.1365-2559.2005.01991.x.View ArticlePubMedGoogle Scholar
- Harris GC, McCulloch TA, Perks G, Fisher C: Malignant perivascular epithelioid cell tumor ("PEComa") of soft tissue: a unique case. Am J Surg Pathol. 2004, 28: 1655-1658.View ArticlePubMedGoogle Scholar
- Lehman NL: Malignant PEComa of the skull base. Am J Surg Pathol. 2004, 28: 1230-1232.View ArticlePubMedGoogle Scholar
- Sadeghi S, Krigman H, Maluf H: Perivascular epithelioid clear cell tumor of the common bile duct. Am J Surg Pathol. 2004, 28: 1107-1110.View ArticlePubMedGoogle Scholar
- Pan CC, Yang AH, Chiang H: Malignant perivascular epithelioid cell tumor involving the prostate. Arch Pathol Lab Med. 2003, 127: E96-98.PubMedGoogle Scholar
- Pan CC, Yu IT, Yang AH, Chiang H: Clear cell myomelanocytic tumor of the urinary bladder. Am J Surg Pathol. 2003, 27: 689-692. 10.1097/00000478-200305000-00013.View ArticlePubMedGoogle Scholar
- Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW: Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. 2005, 29: 1558-1575. 10.1097/01.pas.0000173232.22117.37.View ArticlePubMedGoogle Scholar
- Hornick JL, Fletcher CDM: PEComa: what do we know so far?. Histopathology. 2006, 48: 75-82. 10.1111/j.1365-2559.2005.02316.x.View ArticlePubMedGoogle Scholar
- Dreau D, Foster M, Hogg M, Swiggett J, Holder WD, White RL: Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma. Oncol Res. 2000, 12: 241-51.PubMedGoogle Scholar
- Ezekowitz RA, Mulliken JB, Folkman J: Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992, 326: 1456-1463.View ArticlePubMedGoogle Scholar
- Ezekowitz RA, Mulliken JB, Folkman J: Additional corrections: interferon alfa-2a for hemangiomas of infancy. N Engl J Med. 1995, 333: 595-596. 10.1056/NEJM199508313330913.View ArticlePubMedGoogle Scholar
- Rigby H, Yu W, Schmidt MH, Fernandez CV: Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate. Pediatr Blood Cancer. 2005, 45: 202-6. 10.1002/pbc.20305.View ArticlePubMedGoogle Scholar
- Deenik W, Mooi WJ, Rutgers EJ, Peterse JL, Hart AA, Kroon BB: Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 30 cases. Cancer. 1999, 86: 969-75. 10.1002/(SICI)1097-0142(19990915)86:6<969::AID-CNCR11>3.0.CO;2-Z.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/6/20/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.